Zobrazeno 1 - 10
of 53
pro vyhledávání: ''
Autor:
Bruce A. Littlefield, Elodie Modave, Amy Weaver, Bram Boeckx, Diether Lambrechts, Agnieszka Wozniak, Patrick Schöffski
Publikováno v:
Clinical Cancer Research. 27:3106-3115
Purpose:A randomized phase III study evaluated the efficacy of eribulin versus dacarbazine in patients with advanced liposarcoma and leiomyosarcoma. Improved overall survival (OS) led to approval of eribulin for liposarcoma, but not for leiomyosarcom
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Peter S. Hammerman, Jing Yuan, Lesley A. Mathews Griner, Peter Aspesi, Daniel J. McKay, Gwynn Pardee, Hui Qin Wang, Kelli-Ann Monaco, Ribo Guo, Kenneth Crawford, Stephania Widger, Darrin Stuart, Vesselina G. Cooke, Karen Bui, Felipa A. Mapa, Yuji Mishina, Mariela Jaskelioff, Jeffrey A. Engelman, Paul Fordjour, Emma Labrot, Giordano Caponigro, Stacy Higgins, Jessi Ambrose, John Fuller, Jinsheng Liang, John Green, Scott Delach
Publikováno v:
Clinical Cancer Research. 27:2061-2073
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. Experimental Design: LXH254 was profiled in biochemical, in vitro, and in vivo assay
Autor:
Amy Zhang, Grainne M. O'Kane, Paz Polak, Celia M. T. Greenwood, James Joseph Biagi, Sandra Fischer, Julie M. Wilson, Louis-Martin Boucher, Gun Ho Jang, Zu-Hua Gao, Jennifer J. Knox, Yifan Wang, Yasser Riazalhosseini, Nathaniel Bouganim, Ayelet Borgida, David Valenti, Robert C. Grant, Steven Gallinger, Mehdi Masoomian, Robert E. Denroche, William D. Foulkes, John M. S. Bartlett, Chani Stossel, Maria Raitses-Gurevich, Alain Pacis, Ilinca Lungu, Talia Golan, Simeng Bu, Jean Monlong, T. Cabrera, George Zogopoulos, Celine Domecq, Spring Holter, Jin Yong Patrick Park, Jamil Asselah, Adeline Cuggia
Publikováno v:
WAng, Y, Patrick Park, J Y, Pacis, A, E. Denroche, R, Jang, G H, Zhang, A, Cuggia, A, Domecq, C, Monlong, J, Raitses-Gurevich, M, C. Grant, R, Borgida, A, Holter, S, Stossel, C, Bu, S, Masoomian, M, Lungu, I, Bartlett, J, M. Wilson, J, Gao, Z-H, Riazalhosseini, Y, Asselah, J, Bouganim, N, Cabrera, T, Boucher, L-M, Valenti, D, Biagi, J, M.T Greenwood, C, Polak, P, D. Foulkes, W, Golan, T, M. O'Kane, G, E. Fischer, S, J. Knox, J, Gallinger, S & Zogopoulos, G 2020, ' A preclinical trial and molecularly-annotated patient cohort identify predictive biomarkers in homologous recombination deficient pancreatic cancer ', Clinical Cancer Research . https://doi.org/10.1158/1078-0432.CCR-20-1439
Purpose:Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is
Autor:
Richard Price, Christine Ju, Johanna C. Bendell, Herbert Hurwitz, Xiaoju Max Ma, John Lee, Nalin Tikoo, Christoph Mancao, Lijing Yao, Alex Lovejoy, Alan Nicholas, Stephanie J. Yaung, John F. Palma, Nicolas Sommer
Publikováno v:
Clinical Cancer Research. 26:4010-4017
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma
Publikováno v:
Clin Cancer Res
Purpose: To determine the expression of glucocorticoid receptor (GR) and androgen receptor (AR) in salivary duct carcinoma (SDC) and to analyze the role of these proteins in the development and management of this disease entity. Experimental Design:
Autor:
Genta Nagae, Kazuhiko Koike, Hayato Nakagawa, Yutaka Midorikawa, Shogo Yamamoto, Kenji Tatsuno, Kyoji Moriya, Tadatoshi Takayama, Mitsuhiko Moriyama, Hiroyuki Aburatani
Publikováno v:
Clinical Cancer Research. 25:6217-6227
Purpose:Hepatitis B viral (HBV) DNA is frequently integrated into the genomes of hepatocellular carcinoma (HCC) in patients with chronic HBV infection (chronic HBV, hereafter), whereas the frequency of HBV integration in patients after the disappeara
Autor:
Tobias Herold, Luise Hartmann, Wolfgang Hiddemann, Philipp A. Greif, Daniela Schumacher, Bianka Ksienzyk, Claudia D. Baldus, Bernhard Wörmann, Evelyn Zellmeier, Stephan Wolf, Sebastian Vosberg, Friederike Pastore, Helmut Blum, Stephanie Schneider, Sophie M. Stief, Stefanos A. Bamopoulos, Wolfgang E. Berdel, Ines Hellmann, Stefan Krebs, Alexander Graf, Karsten Spiekermann, Klaus H. Metzeler, Stefan K. Bohlander, Vindi Jurinovic, Nikola P. Konstandin, Raphael Mattes, Dennis Görlich, Martin Neumann, Kathrin Bräundl, Paul Kerbs
Publikováno v:
Clinical Cancer Research. 24:1716-1726
Purpose: To study mechanisms of therapy resistance and disease progression, we analyzed the evolution of cytogenetically normal acute myeloid leukemia (CN-AML) based on somatic alterations. Experimental Design: We performed exome sequencing of matche
Publikováno v:
Clinical Cancer Research. 23:3884-3895
Purpose: Human papillomavirus 16 (HPV-16) is an important risk factor in head and neck cancer (HNC). Studies suggest that miRNAs play an important role in cancer; however, their role in HPV-mediated oncogenesis remains largely unknown. We investigate
Autor:
Wen Jia Zuo, Zhi Ming Shao, Jiong Wu, Guang Yu Liu, Yi-Zhou Jiang, Gen Hong Di, Xin Hu, Y. Wang, Ke Da Yu, Xiao En Xu
Publikováno v:
Clinical Cancer Research. 22:4859-4869
Purpose: Somatic mutations in the tyrosine kinase domain of human epidermal growth factor receptor 2 (HER2) may be an alternative mechanism to HER2 activation and can affect the sensitivity toward HER2-targeted therapies. We aimed to investigate the